Study of 177Lu-PSMA and Stereotactic Radiotherapy vs. Radiotherapy for Patients with Oligometastatic Prostate Cancer

2 1 1

What is this study about?

This clinical trial is focused on studying a type of prostate cancer known as oligometastatic prostate cancer. This condition occurs when prostate cancer has spread to a few other parts of the body. The study is comparing two treatment approaches: one group will receive a combination of a special drug called 177Lu-PSMA I&T and a precise form of radiation therapy known as stereotactic radiotherapy, while the other group will receive only stereotactic radiotherapy. The drug 177Lu-PSMA I&T is given through an intravenous infusion, which means it is administered directly into the bloodstream.

The purpose of the study is to see how well these treatments work in preventing the cancer from getting worse over a period of 12 months. Participants will be randomly assigned to one of the two treatment groups. Throughout the study, regular check-ups and tests will be conducted to monitor the participants’ health and the progress of the cancer. The study aims to understand which treatment is more effective in controlling the cancer and improving the quality of life for patients.

Participants will be closely monitored for any side effects or changes in their condition. The study will also look at how long patients can go without needing additional hormone therapy, which is often used in prostate cancer treatment. The overall goal is to find the best approach to manage oligometastatic prostate cancer and improve outcomes for patients.

1 randomization

Upon joining the study, participants are randomly assigned to one of two groups. One group receives Lu-PSMA combined with stereotactic radiotherapy, while the other group receives radiotherapy alone.

2 treatment administration

Participants in the Lu-PSMA group receive the medication through an intravenous infusion. The specific dosage and frequency are determined by the study protocol and medical team.

Participants in both groups undergo stereotactic radiotherapy, a precise form of radiation therapy targeting cancer cells.

3 monitoring and follow-up

Throughout the study, participants attend regular follow-up appointments to monitor their health and the effectiveness of the treatment. This includes routine blood tests to measure prostate-specific antigen (PSA) levels and imaging tests to assess cancer progression.

Participants complete quality of life assessments using the Functional Assessment of Cancer Therapy – Prostate (FACT-P) questionnaire.

4 end of treatment evaluation

At the end of the treatment period, participants undergo a final evaluation to determine the overall effectiveness of the treatment. This includes assessing PSA progression-free survival and any potential side effects experienced during the study.

5 long-term follow-up

Participants continue to be monitored for a period after the treatment phase to assess long-term outcomes, including overall survival and any late-onset side effects.

Who Can Join the Study?

Patients must have prostate cancer with 1-3 asymptomatic metastatic lesions. These are cancer spots that have spread but do not cause symptoms. They should be 5.0 cm or smaller or less than 250 cm³ in size, as shown by a CT/MRI or WBD-MRI scan.
Patients must be 18 years or older.
Patients must understand the study’s purpose and agree to participate by signing a written consent form.
Patients must have an Eastern Cooperative Oncology Group performance status of 2 or less. This is a scale that measures how well a patient can perform daily activities.
Patients should have a life expectancy of at least 6 months.
Patients must have normal organ and marrow function, which includes:
- Leukocytes (a type of white blood cell) greater than 2,000/µL.
- Absolute neutrophil count (another type of white blood cell) greater than 1,000/µL.
- Platelets (cells that help with blood clotting) greater than 75,000/µL.
- Total bilirubin within normal limits, except for patients with Gilbert’s syndrome.
- AST (SGOT)/ALT (SGPT) levels should be 2.5 times or less than the upper normal limit.
- Creatinine within normal limits.
If the patient is sexually active with a woman who can become pregnant, a condom and another highly effective birth control method must be used during treatment and for 6 months after the last dose. The patient must also agree not to donate sperm for reproduction during this time.
Patients and their female partners must use two acceptable birth control methods starting at the screening visit and continuing until 6 months after the last treatment. One method must be a condom, and the other can be:
- Oral, injected, or implanted hormonal contraception by the female partner.
- Placement of an intrauterine device (IUD) or intrauterine system (IUS) by the female partner.
- Additional barrier method like an occlusive cap with spermicidal foam/gel/film/cream/suppository in the female partner.
- Tubal ligation in the female partner.
- Vasectomy or other procedure resulting in infertility for more than 6 months.
A PSMA-PET/CT positive scan must match with lesions shown on the baseline CT/MRI or WBD-MRI.
Patients must have had their primary tumor treated with surgery and/or radiation. Previous salvage radiation to the prostate bed or pelvis is allowed.
Patients will only enter the treatment phase if the diagnostic PET/CT PSMA SUV max is 3 or higher.
There must be histologic confirmation of cancer, meaning the cancer must be confirmed by examining tissue under a microscope.
Prostate specific antigen (PSA) levels must be 0.2 ng/mL or higher but 50 ng/mL or lower, and Testosterone levels must be 125 ng/dL or higher.
The PSA doubling time (PSADT) must be less than 15 months. This is the time it takes for the PSA level to double, calculated from the time of relapse.
Patients who are unfit for or refuse androgen deprivation therapy (ADT) can participate.
Patients may have had previous systemic therapy and/or ADT related to their primary prostate cancer. They may also have had ADT with salvage radiation therapy.

Who Cannot Join the Study?

Patients who are not male cannot participate in the study.
Patients who are part of a vulnerable population, meaning those who might be at higher risk of harm or exploitation, are not eligible.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

No sites found in this category

Other Sites

Site Name	City	Country	Status
Azienda Unita Sanitaria Locale Della Romagna	Faenza	Italy
Ihisobxk Rcttnwoaj Pmz Lc Sbwhnt Dpr Twdehq Dfmd Aymtebp Ijoe Sermwq	Meldola	Italy

Trial status

Country	Status	Recruitment Start
Italy	Recruiting	01.04.2023

Trial locations

Investigated drugs:

177LU-PSMA-I&T

Lu-PSMA is a type of targeted therapy used in the treatment of prostate cancer. It involves a radioactive substance that binds to a specific protein found on the surface of prostate cancer cells. This allows the radiation to be delivered directly to the cancer cells, helping to destroy them while minimizing damage to surrounding healthy tissue.

Stereotactic Radiotherapy is a form of radiation therapy that delivers high doses of radiation to a precise area. It is used to target and treat small, specific areas of cancer, such as oligometastatic prostate cancer, with minimal impact on surrounding healthy tissues. This therapy is known for its accuracy and effectiveness in controlling cancer growth.

Oligometastatic Prostate Carcinoma – This is a form of prostate cancer where the disease has spread to a limited number of other parts of the body, typically fewer than five metastatic sites. It is considered an intermediate state between localized prostate cancer and widespread metastatic disease. The cancer cells in oligometastatic prostate carcinoma can grow and spread, but they do so at a slower rate compared to more advanced metastatic prostate cancer. The progression of this disease can vary, with some patients experiencing stable disease for extended periods, while others may see a gradual increase in the number of metastases. The condition is often sensitive to hormone therapy, which can help control the growth of cancer cells. Understanding the progression of oligometastatic prostate carcinoma is crucial for determining appropriate treatment strategies.

Trial ID:

2024-519347-15-00

Protocol code:

IRST185.09

NCT ID:

NCT05893381

Trial Phase:

Therapeutic exploratory (Phase II)

Other Trials to Consider

#1 Clinical Trials Search in Europe

Study of 177Lu-PSMA and Stereotactic Radiotherapy vs. Radiotherapy for Patients with Oligometastatic Prostate Cancer

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?